インクレチン関連薬のNAFLD/NASH治療への応用  [in Japanese] Incretin as a Novel Treatment Strategy for NAFLD/NASH  [in Japanese]

Access this Article

Author(s)

    • 武田 泰生 Takeda Yasuo
    • 鹿児島大学医学部・歯学部附属病院薬剤部|鹿児島大学大学院医歯学総合研究科薬物動態制御学分野 Department of Clinical Pharmacy and Pharmacology, Kagoshima University Hospital|Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University
    • 池田 龍二 Ikeda Ryuji
    • 鹿児島大学医学部・歯学部附属病院薬剤部|鹿児島大学大学院医歯学総合研究科薬物動態制御学分野 Department of Clinical Pharmacy and Pharmacology, Kagoshima University Hospital|Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University
    • 近藤 智子 Kondo Tomoko
    • 鹿児島大学医学部・歯学部附属病院薬剤部 Department of Clinical Pharmacy and Pharmacology, Kagoshima University Hospital

Abstract

 Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been recognized as metabolic disorders characterized by fatty accumulation in the liver without alcohol consumption. The diseases can cause metabolic syndromes, consisting of obesity, diabetes mellitus (DM), dyslipidemia and hypertension. For the treatment of NAFLD/NASH, losing weight by exercise or diet remains the standard treatment, because no effective pharmacological therapy has yet been developed for NAFLD/NASH. Two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), stimulate glucose-mediated insulin production in pancreatic β cells. Incretin has also been reported to have various extra-pancreatic effects, including the regulation of hepatic glucose production, appetite and satiety, as well as the stimulation of afferent sensory nerves. Therefore, incretin may have potential as a novel therapeutic agent for NAFLD/NASH.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 136(4), 573-577, 2016

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130005140770
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    JPN
  • ISSN
    0031-6903
  • NDL Article ID
    027267729
  • NDL Call No.
    Z19-411
  • Data Source
    NDL  J-STAGE 
Page Top